Biotech Values

[MiamiGent]

SWTX SpringWorks stock rallies 18% post-market on FDA approval of Ogsiveo
Nov. 27, 2023 6:39 PM ETSpringWorks Therapeutics, Inc. (SWTX)
By: Val Brickates Kennedy, SA News Editor

https://stockcharts.com/h-sc/ui?s=SWTX

SpringWorks Therapeutics (NASDAQ:SWTX) stock rallied 18% in after-hours trading Monday after the company announced the FDA had approved its drug Ogsiveo for the treatment of adult patients with progressing desmoid tumors who require systemic treatment.

The FDA previously granted Ogsiveo breakthrough therapy, fast track and orphan drug designations.

SpringWorks said the drug, also known as nirogacestat, is the first and only treatment approved for adults with desmoid tumors.